SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Montagna, D. Articles by Vitiello, A. Search for Related Content PubMed PubMed Citation Articles by Montagna, D. Articles by Vitiello, A. Related Collections Immunobiology Transplantation Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2001, Vol. 98, No. 12, pp. 3359-3366 IMMUNOBIOLOGY Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy Daniela Montagna, Rita Maccario, Franco Locatelli, Vittorio Rosti, Young Yang, Peggy Farness, Antonia Moretta, Patrizia Comoli, Enrica Montini, and Antonella Vitiello From the BMT Laboratory and BMT Units, Department of Pediatrics, Laboratory of Organ Transplantation, IRCCS Policlinico San Matteo, University of Pavia, Italy; and the Robert Wood Johnson Pharmaceutical Research Institute, San Diego, CA. Adoptive cellular immunotherapy has proven to be a successful approach in preventing and curing cytomegalovirus infection and Epstein-Barr virus-associated lymphomas after bone marrow transplantation. Translation of this approach for preventing leukemia relapse after bone marrow transplantation might require ex vivo priming and long-term maintenance of leukemia blast-specific T cells. To accomplish this goal, procedures were optimized for the in vitro priming of naive CD8 using dendritic cells activated by CD40 ligation, interleukin-12 (IL-12), and IL-7. Using T lymphocytes and dendritic cells obtained from HLA-matched allogeneic bone marrow transplantation donors and leukemia blasts as a source of tumor antigens, anti-acute myeloid leukemia cytotoxic T lymphocytes (CTLs) were induced. In these experiments, it was found that though it is possible to induce CTLs using immature dendritic cells, IL-12, and IL-7, obtaining long-term CTLs requires the presence of CD4 T cells in the priming phase. Using this approach, long-term antileukemia CTL lines could be generated from 4 of 4 bone marrow donors. Because this procedure does not require definition of the target antigen and because it selects responding cells from a virgin T-cell repertoire, its general application is suggested in adoptive immunotherapy and in the definition of tumor rejection antigens. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Di Nardo, M. H. Braff, K. R. Taylor, C. Na, R. D. Granstein, J. E. McInturff, S. Krutzik, R. L. Modlin, and R. L. Gallo Cathelicidin Antimicrobial Peptides Block Dendritic Cell TLR4 Activation and Allergic Contact Sensitization J. Immunol., February 1, 2007; 178(3): 1829 - 1834. [Abstract] [Full Text] [PDF] D. Montagna, R. Maccario, F. Locatelli, E. Montini, S. Pagani, F. Bonetti, L. Daudt, I. Turin, D. Lisini, C. Garavaglia, et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia Blood, December 1, 2006; 108(12): 3843 - 3850. [Abstract] [Full Text] [PDF] D. Montagna, L. Daudt, F. Locatelli, E. Montini, I. Turin, D. Lisini, G. Giorgiani, M. E. Bernardo, and R. Maccario Single-Cell Cloning of Human, Donor-Derived Antileukemia T-Cell Lines for In vitro Separation of Graft-versus-Leukemia Effect from Graft-versus-Host Reaction. Cancer Res., July 15, 2006; 66(14): 7310 - 7316. [Abstract] [Full Text] [PDF] S. Maia, W. N. Haining, S. Ansen, Z. Xia, S. A. Armstrong, N. P. Seth, P. Ghia, M. L. den Boer, R. Pieters, S. E. Sallan, et al. Gene Expression Profiling Identifies BAX-{delta} as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia Cancer Res., November 1, 2005; 65(21): 10050 - 10058. [Abstract] [Full Text] [PDF] M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF] P. Comoli, S. Basso, A. Azzi, A. Moretta, R. De Santis, F. Del Galdo, R. De Palma, U. Valente, A. Nocera, F. Perfumo, et al. Dendritic Cells Pulsed with Polyomavirus BK Antigen Induce Ex Vivo Polyoma BK Virus-Specific Cytotoxic T-Cell Lines in Seropositive Healthy Individuals and Renal Transplant Recipients J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3197 - 3204. [Abstract] [Full Text] [PDF] A. N. Rad, G. Pollara, S. M. A. Sohaib, C. Chiang, B. M. Chain, and D. R. Katz The Differential Influence of Allogeneic Tumor Cell Death via DNA Damage on Dendritic Cell Maturation and Antigen Presentation Cancer Res., August 15, 2003; 63(16): 5143 - 5150. [Abstract] [Full Text] [PDF] M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF] H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020